

SPONSORSHIP AGREEMENT

This Sponsorship Agreement (“*Agreement*”), entered into as of 13th March 2023 (“*Effective Date*”), is by and between **Amarin Switzerland GmbH Sweden filial**, reg. no. 516412-6558, with an office located at c/o TMF Sweden AB, Sergels Torg 12, 111 57 Stockholm, Sweden (“*AMARIN*”), and **RIKSFÖRBUNDET HJÄRTLUNG LIDINGÖ**, with an office located at LARSBERGSTORGET 9 18139 Lidingö, Sweden (“*SPONSEE*”). AMARIN and SPONSEE are each referred to herein as a “*Party*” and collectively as the “*Parties*.”

RECITALS

WHEREAS, SPONSEE would like AMARIN’s support for its Educational Members meeting arranged by PAG Heart Lung Lidingö which is taking place on 21st March 2023 (“*Event*”), and AMARIN would like to assist the SPONSEE by providing it with Funding to support the development, enhancement or implementation of the Event.

NOW, THEREFORE, in consideration of the mutual promises contained herein, the Parties agree as follows:

1. **SUPPORT.** The details of the Event are set forth in Exhibit A, including the responsibilities of the Parties in support thereof, as applicable.
2. **FUNDING.**
 - 2.1. Although no direct financial consideration is being exchanged under this Agreement, AMARIN and SPONSEE both acknowledge and agree that the provision and payment of a Speaker at the Event by AMARIN is a mutually beneficial arrangement that is sufficient by itself to constitute good and valuable consideration in return for the benefits received by AMARIN hereunder (“*Funding*”). There will be no further payments by AMARIN in relation to the Event, unless expressly specified in this Agreement.
 - 2.2. SPONSEE shall ensure that the Funding will:
 - 2.2.1. not be used for financing of any entertainment or leisure activity;
 - 2.2.2. only be used for the Event and shall not be used, in whole or in part, to subsidize or pay for other opportunities except as otherwise agreed to in writing by the Parties;
 - 2.2.3. Not be paid, granted or distributed to any other organization or any individual other than to pay reasonable compensation for items and services provided to SPONSEE in connection with the Event.
 - 2.3. SPONSEE shall return to AMARIN any portion of the Funding that is not used for the Event in accordance with this Agreement. If SPONSEE is unable to spend the Funding for the Event, SPONSEE shall promptly return the Funding to Amarin.
 - 2.4. SPONSEE shall maintain objectivity and independence with respect to any activities developed, sponsored or otherwise supported by Funding, and SPONSEE will not permit influence by AMARIN beyond the usual input SPONSEE seeks from stakeholders.
3. **PUBLICITY.**
 - 3.1. Any SPONSEE limitation as to the manner in which AMARIN references its support for the Event shall be set forth in Exhibit A. Absent such a limitation, and except as otherwise set forth in this Agreement, AMARIN shall retain sole discretion as to the manner in which it references its support for the Event.
 - 3.2. SPONSEE shall not, on AMARIN’s behalf, initiate any communication with a physician or healthcare professional without the prior written approval of AMARIN, and any such communication shall follow a written protocol and script that is preapproved in writing by AMARIN.
 - 3.3. Neither Party shall be prohibited from disclosing the Funding provided by AMARIN pursuant to this Agreement.

4. INTELLECTUAL PROPERTY

- 4.1. AMARIN hereby grants SPONSEE, during the Term of this Agreement, a limited, non-exclusive, non-transferable, non-sublicensable, fully paid-up license to display the AMARIN trademarks or service marks set forth in Exhibit B (individually and collectively, "**AMARIN TM**"), and only for the purpose of identifying AMARIN as a sponsor of the Event. SPONSEE's use of the AMARIN TM in any manner other than that expressly set forth in this Agreement is prohibited. No title to, or ownership of, the AMARIN TM, or any portion thereof, is transferred to SPONSEE. SPONSEE may not alter, modify or change in any way the AMARIN TM. Upon termination of this Agreement, SPONSEE shall cease any and all use of the AMARIN TM.
- 4.2. SPONSEE hereby grants AMARIN, during the Term of this Agreement, a limited, non-exclusive, non-transferable, non-sublicensable, fully paid-up license to display the SPONSEE trademarks or service marks set forth in Exhibit C (individually and collectively, "**SPONSEE TM**"), and only for purposes of identifying SPONSEE as the Event organizer. AMARIN's use of the SPONSEE TM in any manner other than that expressly set forth in this Agreement is prohibited. No title to, or ownership of, the SPONSEE TM, or any portion thereof, is transferred to AMARIN. AMARIN may not alter, modify or change in any way the SPONSEE TM. Upon termination of this Agreement, AMARIN shall cease any and all use of the SPONSEE TM.
- 4.3. Unless otherwise expressly agreed by the Parties in writing, AMARIN owns the copyright in all copyrightable works provided or created by it hereunder, in any form, format medium or means of transmission or distribution ("**AMARIN Materials**"). SPONSEE may not copy or distribute AMARIN Materials without AMARIN's prior written consent. Any modification of AMARIN Materials requires AMARIN's prior written consent, including AMARIN's review and approval of the modifications.
- 4.4. Unless otherwise expressly agreed by the Parties in writing, SPONSEE owns the copyright in all copyrightable works provided or created by it hereunder, in any form, format medium or means of transmission or distribution ("**SPONSEE Materials**"). AMARIN may not copy or distribute SPONSEE Materials without SPONSEE's prior written consent. Any modification of SPONSEE Materials requires SPONSEE's prior written consent, including SPONSEE's review and approval of the modifications.

5. SPONSEE REPRESENTATIONS

- 5.1. SPONSEE further agrees that:
 - 5.1.1. it is responsible for the organization and conduct of the Event, i.e. AMARIN has no influence on the agenda or the selection of speakers or topics;
 - 5.1.2. it shall manage and run the Event (if virtual) on a secure platform which is suitable of the intended purpose and number of attendees;
 - 5.1.3. in no event shall the Funding be used by SPONSEE to make any direct or indirect payment or any other transfer of value to any healthcare provider, institution or entity except as otherwise agreed in writing by AMARIN; and
 - 5.1.4. it shall conduct all activities relating to the Event and perform its obligations under this Agreement in compliance with any and all applicable laws and regulations as well as in compliance with the IFPMA's Code of Practice, EFPIA's Code of Practice and the Swedish Association of the Pharmaceutical Industry's ("**LIF**") Code of Conduct;
 - 5.1.5. it shall ensure that access to the Event and in particular to any industry fair and booths (physically and/or virtually, as applicable) will only be granted to Event attendees in compliance with applicable laws and regulations governing healthcare advertising and promotion of medicinal products; and
 - 5.1.6. it shall process any personal data in connection with the Event and the performance of its obligations under this Agreement in compliance with applicable data protection laws and regulations, including under the EU General Data Protection Regulation (GDPR). SPONSEE shall provide to AMARIN any model consent forms and related notices that SPONSEE will provide to and plans to obtain from Event attendees.

6. SEPARATION AND TRANSPARENCY

- 6.1. The payment of the Funding under this Agreement is independent of any sales transaction between SPONSEE and AMARIN. The Parties agree that this Agreement is not intended directly or indirectly to compensate SPONSEE, its employees or any attendees at the Event for purchasing, ordering, prescribing, using or recommending AMARIN

products or services. SPONSEE and its employees are not required or expected to purchase, use, prescribe, order, recommend, promote or advertise AMARIN products or services as a condition of this Agreement.

- 6.2.** For transparency purposes AMARIN intends to document and publish/report all direct and indirect transfers of value (“*ToVs*”) to SPONSEE and any other relevant recipients of the Funding under this Agreement (“*Recipients*”), including without limitation, the SPONSEE’s identity and address, the amount, and the purpose of the Funding in accordance with applicable legal and regulatory requirements and the IFPMA's Code of Practice, EFPIA's Code of Practice and LIF's Code of Conduct. SPONSEE is responsible for notifying all Recipients of the Funding of AMARIN’s commitment to transparency and intention to document and publish/report all ToVs to such recipients.
- 6.3.** SPONSEE shall provide the Data Protection Notice attached to this Agreement as Exhibit D to any Recipients. SPONSEE and Recipients may object to the disclosure of his/her personal data as outlined in Exhibit D. If SPONSEE or any Recipient objects, the information will be documented, reported and published by AMARIN in an aggregated form without any personal data, as further described in Exhibit B. SPONSEE shall immediately inform AMARIN about SPONSEE or any Recipient’s decision to object.

7. INDEMNIFICATION

- 7.1. By SPONSEE.** SPONSEE shall indemnify and hold harmless AMARIN, its affiliates, and their respective employees, officers, directors, agents, representatives (all of the foregoing, the “*AMARIN Indemnified Parties*”) for any losses, damages, claims, expense, fines, penalties or liabilities suffered by the AMARIN Indemnified Parties (including, without limitation, reasonable legal fees and disbursements as incurred in connection therewith) in connection with a third-party claim and to the extent arising out of (i) a SPONSEE Indemnified Parties’ material breach of this Agreement; (ii) a SPONSEE Indemnified Parties’ negligence, unlawful acts, or willful misconduct; or (iii) any claim that the SPONSEE TM, when used in accordance with the terms of this Agreement, infringes the intellectual property rights of a third-party, except to the extent that such claims are attributable to an AMARIN Indemnified Parties’ negligence, unlawful acts, or willful misconduct.
- 7.2. By AMARIN.** AMARIN shall indemnify and hold harmless SPONSEE, its affiliates, and their respective employees, officers, directors, agents, representatives (all of the foregoing, the “*SPONSEE Indemnified Parties*”) for any losses, damages, claims, expense, fines, penalties or liabilities suffered by the SPONSEE Indemnified Parties (including, without limitation, reasonable legal fees and disbursements as incurred in connection therewith) in connection with a third-party claim and to the extent arising out of (i) an AMARIN Indemnified Parties’ material breach of this Agreement; (ii) an AMARIN Indemnified Parties’ negligence, unlawful acts, or willful misconduct; or (iii) any claim that the AMARIN TM, when used in accordance with the terms of this Agreement, infringes the intellectual property rights of a third-party, except to the extent that such claims are attributable to a SPONSEE Indemnified Parties’ negligence, unlawful acts, or willful misconduct.
- 7.3. Indemnification Procedure.** A Party that intends to claim indemnification (“*Indemnitee*”) under this Section 7 shall promptly notify the indemnifying Party (“*Indemnitor*”) in writing of any third-party claim, suit, or proceeding included within the indemnification described in this Section 7 (each a “*Claim*”) with respect to which the Indemnitee intends to claim such indemnification, and the Indemnitor shall have sole control of the defense and settlement of the Claim. The Indemnitee shall have the right to participate, at its own expense, with counsel of its own choosing in the defense or settlement of the Claim. The indemnification obligations under this Section 7 shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the consent of the Indemnitor. The Indemnitee and its employees, at the Indemnitor’s request and expense, shall provide full information and reasonable assistance to Indemnitor and its legal representatives with respect to Claims.

8. LIMITATION OF LIABILITIES

- 8.1.** WITH THE EXCEPTION OF ITS INDEMNITY OBLIGATIONS SET FORTH IN SECTION 7.2, OR ANY LIABILITY WHICH CANNOT BE LIMITED BY APPLICABLE LAW, AMARIN SHALL NOT BE LIABLE TO SPONSEE FOR ANY CONSEQUENTIAL, INCIDENTAL, OR INDIRECT DAMAGES OR EXPENSES, INCLUDING DAMAGES FOR LOST PROFITS, LOSS OF OPPORTUNITY OR USE OF ANY KIND, SUFFERED BY SPONSEE UNDER ANY LEGAL OR EQUITABLE THEORY, INCLUDING BREACH OF CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY AND OTHERWISE, AND WHETHER

OR NOT AMARIN HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. IN ANY EVENT, THE TOTAL LIABILITY OF AMARIN TO SPONSEE OR ANY THIRD-PARTY ARISING OUT OF THIS AGREEMENT AND OTHER RELATED AGREEMENTS IN CONNECTION WITH ANY CLAIM OR TYPE OF DAMAGE (WHETHER IN CONTRACT OR TORT) WILL NOT EXCEED THE AMOUNT OF FUNDING PROVIDED BY AMARIN TO SPONSEE UNDER THIS AGREEMENT. THESE LIMITATIONS SHALL APPLY NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY.

9. CONFIDENTIALITY

In the context of this Agreement and/or the Event, the Parties recognize that SPONSEE may come in contact with or become familiar with information that AMARIN or its affiliates may consider confidential (the “**Confidential Information**”). SPONSEE agrees to maintain and ensures that, its employees, partners, contractors maintain the confidentiality of all Confidential Information and not to discuss or divulge it to anyone other than appropriate AMARIN personnel or their designees. SPONSEE (i) shall not use any Confidential Information and (ii) shall not in any way exploit Confidential Information commercially and/or non-commercially, except as required for the conduct of the Event or to fulfill obligations under the terms of this Agreement. Upon AMARIN’s request at any time, SPONSEE shall return to AMARIN or destroy any materials in SPONSEE’s and Recipient’s possession that include Confidential Information. SPONSEE may disclose Confidential Information if, and to the extent, required by law, by any governmental or other regulatory authority, by a court or other authority of competent jurisdiction provided that, to the extent it is legally permitted to do so, it gives AMARIN as much notice of such disclosure as possible and, where notice of disclosure is not prohibited, it takes into account the reasonable requests of AMARIN in relation to the content of such disclosure.

10. TERM & TERMINATION.

10.1. This Agreement shall commence on the Effective Date and shall terminate on 30th March 2023 (“**Termination Date**”).

10.2. Either Party may terminate this Agreement prior to the Termination Date (“**Early Termination Date**”) if the other Party materially breaches any term of condition of this Agreement and fails to cure such breach within ten (10) business days after receipt of written notice of such breach from the non-breaching Party.

10.3. If either Party terminates this Agreement prior to the Termination Date, irrespective of the reason, then SPONSEE shall refund the Funding to AMARIN within ten (10) days of the Early Termination Date.

10.4. Section 3, Section 4, Section 6, Section 7, Section 8, Section 9 and section 10 and any other provision that by its nature should survive any expiration or termination of this Agreement, will survive any expiration or termination of this Agreement and remain in full force and effect in accordance with its terms. The expiration or termination of this Agreement shall not relieve any Party of any liability or obligation that accrued hereunder prior to the effective date of such expiration or termination nor shall it preclude any Party from pursuing all rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement.

11. MISCELLANEOUS

11.1. Independent Contractor. The status of AMARIN and SPONSEE hereunder is solely that of independent companies interacting with each other at arm’s length. This Agreement shall not create an agency, partnership, joint venture, or employer/employee relationship between the Parties, and nothing hereunder shall be deemed to authorize either Party to act for, represent or bind the other except as expressly provided in this Agreement.

11.2. Notice. All notices given pursuant hereto by one Party to the other Party shall be in writing and shall be deemed given (i) when hand-delivered by messenger; (ii) when received by the addressee, if sent by an overnight courier with automated delivery confirmation; or (iii) three (3) days after being mailed in prepaid, registered or certified postage, in each case to the appropriate addresses set forth below (or to such other addresses as a Party may designate as to itself by notice to the other Party):

If to SPONSEE:

Riksförbundet Hjärtlung Lidingö

Larsbergorget 9, 18139 Lidingö

If to AMARIN:

Amarin Switzerland GmbH Sweden filial.c/o TMF Sweden AB,
Sergels Torg 12,
111 57 Stockholm,
Sweden
Attn: Anna-Karin Åhman

With a copy to: Amarin Pharmaceuticals Ireland Limited,
Iconic Offices,
The Greenway,
Block C Ardilaun Court,
112 – 114 St Stephens Green,
Dublin 2, D02 TD28, Ireland
Attn: Legal Department

- 11.3. Conflicting Terms.** In the event of a conflict between the terms of this Agreement and any exhibit hereto, the terms and conditions contained in this Agreement shall prevail. No terms of any purchase order or invoice will add to, modify or supersede the terms of this Agreement.
- 11.4. Force Majeure.** Neither Party shall lose any rights hereunder or be liable to the other Party for damages or losses on account of failure of performance by the breaching Party if such failure is occasioned by acts of nature, war, fire, explosion, flood, strike, lockout, embargo, act of God, or any other similar cause beyond the reasonable control of the breaching Party; provided that the Party claiming force majeure uses diligent efforts to avoid, minimize the effects of, or remedy such force majeure and gives prompt notice to the other Party stating the period of time such force majeure is expected to continue.
- 11.5. Severability; Waiver.** The invalidity or unenforceability of any term or provision of this Agreement shall not affect the validity or enforceability of any other term or provision of this Agreement. Except as expressly set forth herein, the failure of either Party to enforce any provision of this Agreement shall not be deemed a waiver of such Party's right to subsequently enforce such provision.
- 11.6. Entire Agreement; Amendment.** This Agreement, together with any exhibit, each of which are hereby incorporated herein by reference, constitutes the entire agreement between the Parties hereto relating to the subject matter hereof and supersedes all prior or contemporaneous negotiations, representations, agreements and understandings of the Parties relating thereto, whether written or oral. Except as expressly set forth herein, no subsequent alteration, amendment, change, or addition to this Agreement, including the exhibits, shall be binding upon the Parties unless in writing and duly executed by the Parties.
- 11.7. Assignment.** Neither Party shall, without the prior written consent of the other Party (such consent not to be unreasonably withheld), assign or transfer this Agreement to any third-party, and any such prohibited assignment or transfer shall be void, however, AMARIN shall be entitled to assign or transfer any or all of its rights and obligations under this Agreement to any of its affiliates.
- 11.8. No Third-Party Beneficiaries.** Except as set forth in Section 7 with respect to indemnification, the Parties do not confer any rights or remedies upon any entity other than the Parties to this Agreement and their respective successors and permitted assigns.
- 11.9. No Partnership.** The Parties are independent contractors and nothing in this Agreement implies any partnership, agency, joint venture or employment relationship between the Parties, their affiliates or personnel.
- 11.10. Governing Law.** This Agreement, and resolution of all disputes and any remedies relating thereto, shall be governed by and construed in accordance with the laws of Sweden, irrespective of the choice of law stipulations,

and the Parties each irrevocably agree to submit any unresolved dispute or claims to the exclusive jurisdiction of the Swedish courts with the District Court of Stockholm (Sw. *Stockholms tingsrätt*) as the first instance.

11.11. Binding Effect. This Agreement shall be binding upon and shall inure to the benefit of the Parties and their respective successors and permitted assigns.

11.12. Interpretation. The terms and conditions of this Agreement are the result of negotiations between the Parties. The Parties intend that this Agreement shall not be construed in favor of or against either Party by reason of the extent to which such Party or its professional advisors and representatives participated in the preparation or drafting of this Agreement.

11.13. Headings. All headings and captions in this Agreement are inserted for convenience of reference only and shall not affect the meaning or interpretation of any provision hereof.

11.14. Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original signature, but all of which together shall constitute one and the same instrument. A signed copy of this Agreement delivered by email or other means of electronic transmission (to which a PDF copy is attached) shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

[signature page follows]

IN WITNESS WHEREOF, the Parties have caused this Sponsorship Agreement to be executed by their duly authorized representatives as of the Effective Date.

Amarin Switzerland GmbH Sweden filial

DocuSigned by:
Anna-Karin Åhman
By: _____
509CB221071947E...
Name: Anna-Karin Åhman
Title: Commercial Director
Date: 3/15/2023 | 08:09 EDT

Riksförbundet Hjärtlung Lidingö

DocuSigned by:
Anders Gustafson
By: _____
CFB45E4034FA4D4...
Name: Anders Gustafson
Title: Ordförande
Date: 3/15/2023 | 07:58 EDT



EXHIBIT A
EVENT DETAILS

1. DESCRIPTION OF EVENT

Title: PAG Meeting with speaker Felix Böhm

Venue: Nya Föreningsgården, Larsbergstorget 9, 18139 Lidingö

Date: 21-03-2023

Chairpersons: Anders Gustafson,

Event Agenda and Speakers: Felix Bohm

Event website: N/A

Event Organisers/Other Recipients of Funding:

Attendees: Approximately 20 healthcare professionals from Sweden.

Purposes: Educational Members meeting arranged by PAG HeartLung Lidingö focusing on CV disease and dyslipidemias. The Lidingö chapter of The HeartLung Association has expressed an interest to learn more about and raise awareness around CV risk and dyslipidemias and asked AMRN for the financial support to invite a specific SL to educate about the topic.

2. SPONSEE RECOGNITION OF AMARIN

In consideration of the Funding, AMARIN shall receive the following sponsorship benefits:

- 2.1.** Attendance of 1 AMARIN representatives (MSL) at the Event free of charge; and
- 2.2.** AMARIN to be mentioned as a sponsor of the Event to the meeting attendees.

EXHIBIT B
AMARIN TM

“Not applicable.”

EXHIBIT C
SPONSEE TM

“Not applicable.”

EXHIBIT D
DATA PROTECTION NOTICE

Amarin Switzerland GmbH Sweden filial, reg. no. 516412-6558, c/o TMF Sweden AB, Sergels Torg 12, 111 57 Stockholm, Sweden ("**Amarin**") is responsible for the processing of the personal data of **RIKSFÖRBUNDET HJÄRTLUNG LIDINGÖ** or any other healthcare organisation, academic institution or patient organisation that is a recipient of any of the Amarin Funding in respect of the sponsored event "**e PAG Meeting with speaker Felix Böhm J**" ("**Recipient**") as controller (as defined by the EU General Data Protection Regulation ("**GDPR**"). The Recipient can contact Amarin at any time at Sebastian.goebel@amarincorp.eu

In accordance with the International Federation of Pharmaceutical Manufacturers & Association's ("**IFPMA**") Code of Practice and the European Federation of Pharmaceutical Industries and Associations' ("**EFPIA**") Code of Practice and the Swedish Association of the Pharmaceutical Industry's ("**LIF**") Code of Conduct, Amarin supports and intends to contribute to the implementation of transparency disclosures in relation to collaborations between the industry and healthcare organizations, patient organisations and academic institutions and related transfers of value made by Amarin.

What categories of personal data will be processed?

Amarin will document the following information and prepare reports relating to payments and other transfers of value made directly or indirectly to Recipient in connection with the Sponsorship Agreement ("**Agreement**"):

- name and address of Recipient,
- existence and nature of the relationship with Amarin,
- actual services rendered by Recipient,
- direct and indirect payments, compensation, expense reimbursement, ownership or investment interest, or other transfers of value provided to Recipient by Amarin.

Such information will, in accordance with the disclosure requirements in Sweden be published on a publicly accessible website operated by Amarin or any of its affiliated group companies or on a central platform, as provided by or on behalf of IFPMA, EFPIA or LIF, such as the collaboration data base (Sw. *samarbetsdatabas*) provided by LIF's website.

Amarin will disclose and publish Recipient' data in personal identifiable form unless Recipient has objected to the disclosure and publication of Recipient's personal data. If Recipient objects, any information regarding transfers of value made to Recipient in connection with the Agreement will be reported and published for the relevant reporting period only in aggregated and anonymized form, i.e., without being attributable to Recipient.

The processing of Recipient's personal data for documentation and reporting purposes, including a potential anonymization before publication in aggregated form, will be based on the necessity of the processing in order to safeguard Amarin's legitimate interests in ensuring and documenting compliance with applicable legal and regulatory requirements and industry standards, including under the IFPMA's Code of Practice, EFPIA's Code of Practice and LIF's Code of Conduct.

Will Recipient's personal data be processed outside the EEA?

Recipient's personal data may be transferred to or otherwise processed by the above recipients in a country outside the EEA ("**Third Country**"), which may not provide for the same level of data protection as considered adequate in the EEA. In these cases, Amarin will ensure by taking appropriate safeguards, such as by entering into agreements on the basis of standard contractual clauses and by implementing supplementary measures, that Recipient's personal data will be adequately protected as required under EEA data protection laws. In relation to Amarin's

pharmacovigilance obligations, the transfer to Amarin's affiliated group companies and authorities in Third Countries is further necessary to comply with Amarin's legal obligations for important reasons of public interests in the area of public health.

How long will Recipient's personal data be stored?

Recipient's personal data will be stored by Amarin for purposes of internal documentation for a period of five years from the time of publication. In case Recipient has not objected to the disclosure of Recipient's personal data, Recipient's personal data will remain in the public domain, except as required otherwise to comply with applicable legal and regulatory requirements.

Recipient's personal data will be deleted thereafter, except any further storage is necessary to comply with Amarin's legal obligations (such as data retention obligations for seven years after the end of the business relationship with Recipient or other legal requirements) or to establish, exercise or defend our legal claims.

What rights does Recipient have?

To the extent Recipient is affected by the data processing carried out by Amarin, Recipient has the right subject to and in accordance with applicable legal provisions

- to obtain information on the personal data processed concerning Recipient and to obtain a copy of such data (right of access);
- to obtain the rectification of any inaccurate personal data and, having regard to the purposes of the processing, the completion of incomplete personal data (right to rectification);
- if there are legitimate reasons, to request the deletion of the personal data (right to erasure);
- to request the restriction of the processing of the personal data, if the legal requirements are met (right to restriction of processing);
- if the legal requirements are met, to receive the personal data provided by Recipient in a structured, commonly used and machine-readable format and to transfer this personal data to another controller or, if technically feasible, to have it transferred by Amarin (right to data portability); and

Recipient further has the right to object, in accordance with the statutory provisions, to the processing of personal data, which is necessary for the purpose of Amarin's legitimate interests, on grounds relating to Recipient's particular situation (**right to object**). **In particular, Recipient has the right to object to the processing and publication of Recipient's personal data (including Recipient's name, address, and the concrete amount of the transfer of value made directly or indirectly to Recipient by Amarin in connection with the Agreement within the relevant reporting period) on a publicly accessible website as further described above.**

Without prejudice to any other remedies, Recipient also has the right to lodge a complaint with a supervisory authority at any time. In Sweden, the competent supervisory authority is the Swedish Authority for Privacy Protection (Sw. *Integritetsskyddsmyndigheten*): <https://www.imy.se/en/individuals/forms-and-e-services/file-a-gdpr-complaint/>.

In order to exercise rights (including the withdrawal of consent), as well as in the event of questions regarding the processing of Recipient's personal data, please contact Amarin at any time using the contact details set out above.